File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
  • Basic View
  • Metadata View
  • XML View
TitlePredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
 
AuthorsBonino, F9 12
Marcellin, P15
Lau, GKK4
Hadziyannis, S14
Jin, R5
Piratvisuth, T3
Germanidis, G2
Yurdaydin, C6
Diago, M7
Gurel, S16
Lai, MY10
Brunetto, MR11
Farci, P13
Popescu, M1
McCloud, P8
 
Issue Date2007
 
PublisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
 
CitationGut, 2007, v. 56 n. 5, p. 699-705 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2005.089722
 
AbstractOBJECTIVE: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated. METHODS: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20,000 copies/ml. RESULTS: In logistic regression analyses across all treatment arms, peginterferon alpha-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p<0.001), the latter responding better to the combination than to peginterferon alpha-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon alpha-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy. CONCLUSIONS: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon alpha-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.
 
ISSN0017-5749
2013 Impact Factor: 13.319
 
DOIhttp://dx.doi.org/10.1136/gut.2005.089722
 
PubMed Central IDPMC1942152
 
ISI Accession Number IDWOS:000245780200020
 
DC FieldValue
dc.contributor.authorBonino, F
 
dc.contributor.authorMarcellin, P
 
dc.contributor.authorLau, GKK
 
dc.contributor.authorHadziyannis, S
 
dc.contributor.authorJin, R
 
dc.contributor.authorPiratvisuth, T
 
dc.contributor.authorGermanidis, G
 
dc.contributor.authorYurdaydin, C
 
dc.contributor.authorDiago, M
 
dc.contributor.authorGurel, S
 
dc.contributor.authorLai, MY
 
dc.contributor.authorBrunetto, MR
 
dc.contributor.authorFarci, P
 
dc.contributor.authorPopescu, M
 
dc.contributor.authorMcCloud, P
 
dc.date.accessioned2010-04-12T01:39:05Z
 
dc.date.available2010-04-12T01:39:05Z
 
dc.date.issued2007
 
dc.description.abstractOBJECTIVE: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated. METHODS: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20,000 copies/ml. RESULTS: In logistic regression analyses across all treatment arms, peginterferon alpha-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p<0.001), the latter responding better to the combination than to peginterferon alpha-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon alpha-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy. CONCLUSIONS: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon alpha-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationGut, 2007, v. 56 n. 5, p. 699-705 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2005.089722
 
dc.identifier.doihttp://dx.doi.org/10.1136/gut.2005.089722
 
dc.identifier.isiWOS:000245780200020
 
dc.identifier.issn0017-5749
2013 Impact Factor: 13.319
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC1942152
 
dc.identifier.pmid17127704
 
dc.identifier.scopuseid_2-s2.0-34247538953
 
dc.identifier.urihttp://hdl.handle.net/10722/57523
 
dc.languageeng
 
dc.publisherB M J Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
 
dc.rightsGut. Copyright © B M J Publishing Group.
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshAntiviral Agents - therapeutic use
 
dc.subject.meshHepatitis B, Chronic - drug therapy - virology
 
dc.subject.meshInterferon Alfa-2a - therapeutic use
 
dc.subject.meshPolyethylene Glycols - therapeutic use
 
dc.subject.meshLamivudine - therapeutic use
 
dc.titlePredicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Bonino, F</contributor.author>
<contributor.author>Marcellin, P</contributor.author>
<contributor.author>Lau, GKK</contributor.author>
<contributor.author>Hadziyannis, S</contributor.author>
<contributor.author>Jin, R</contributor.author>
<contributor.author>Piratvisuth, T</contributor.author>
<contributor.author>Germanidis, G</contributor.author>
<contributor.author>Yurdaydin, C</contributor.author>
<contributor.author>Diago, M</contributor.author>
<contributor.author>Gurel, S</contributor.author>
<contributor.author>Lai, MY</contributor.author>
<contributor.author>Brunetto, MR</contributor.author>
<contributor.author>Farci, P</contributor.author>
<contributor.author>Popescu, M</contributor.author>
<contributor.author>McCloud, P</contributor.author>
<date.accessioned>2010-04-12T01:39:05Z</date.accessioned>
<date.available>2010-04-12T01:39:05Z</date.available>
<date.issued>2007</date.issued>
<identifier.citation>Gut, 2007, v. 56 n. 5, p. 699-705</identifier.citation>
<identifier.issn>0017-5749</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/57523</identifier.uri>
<description.abstract>OBJECTIVE: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated. METHODS: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of &lt;20,000 copies/ml. RESULTS: In logistic regression analyses across all treatment arms, peginterferon alpha-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon alpha-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p&lt;0.001), the latter responding better to the combination than to peginterferon alpha-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon alpha-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon alpha-2a with or without lamivudine therapy. CONCLUSIONS: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon alpha-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon alpha-2a with or without lamivudine.</description.abstract>
<language>eng</language>
<publisher>B M J Publishing Group. The Journal&apos;s web site is located at http://gut.bmjjournals.com/</publisher>
<rights>Gut. Copyright &#169; B M J Publishing Group.</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Antiviral Agents - therapeutic use</subject.mesh>
<subject.mesh>Hepatitis B, Chronic - drug therapy - virology</subject.mesh>
<subject.mesh>Interferon Alfa-2a - therapeutic use</subject.mesh>
<subject.mesh>Polyethylene Glycols - therapeutic use</subject.mesh>
<subject.mesh>Lamivudine - therapeutic use</subject.mesh>
<title>Predicting response to peginterferon &#945;-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0017-5749&amp;volume=56&amp;issue=5&amp;spage=699&amp;epage=705&amp;date=2007&amp;atitle=Predicting+response+to+peginterferon+&#945;-2a,+lamivudine+and+the+two+combined+for+HBeAg-negative+chronic+hepatitis+B</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1136/gut.2005.089722</identifier.doi>
<identifier.pmid>17127704</identifier.pmid>
<identifier.pmcid>PMC1942152</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-34247538953</identifier.scopus>
<identifier.isi>WOS:000245780200020</identifier.isi>
<bitstream.url>http://hub.hku.hk/bitstream/10722/57523/1/134648.pdf</bitstream.url>
</item>
Author Affiliations
  1. F. Hoffmann-La Roche AG
  2. Papageorgiou General Hospital
  3. Prince of Songkla University
  4. The University of Hong Kong
  5. Beijing Youan Hospital
  6. Ankara Üniversitesi
  7. Hospital General Universitario de Valencia
  8. Roche
  9. Università di Pisa
  10. National Taiwan University Hospital
  11. Azienda Ospedaliera-Universitaria Pisana
  12. IRCCS Foundation Rome
  13. Università degli Studi di Cagliari
  14. Henry Dunant Hospital
  15. Hopital Beaujon
  16. Uludağ Üniversitesi